Organization
Royal National Hospital of Rheumatic Diseases, Bath, United Kingdom
2 abstracts
Abstract
BIMEKIZUMAB MAINTAINED EFFICACY RESPONSES THROUGH 52 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE 3 STUDIESOrg: Royal National Hospital of Rheumatic Diseases, Bath, United Kingdom, Centre for Therapeutic Innovation, University of Bath, Department of Life Sciences, Bath, United Kingdom, University of Occupational and Environmental Health, The First Department of Internal Medicine, Kitakyushu, Fukuoka, Japan, Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, UCB Pharma, Slough, United Kingdom,
Abstract
BIMEKIZUMAB-TREATED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS SHOWED SUSTAINED ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AND REMISSION: UP TO 2-YEAR RESULTS FROM TWO PHASE 3 STUDIESOrg: Nuffield Orthopaedic Centre, Oxford, United Kingdom, Oxford University Hospitals NHS Trust, University of Oxford and Oxford Biomedical Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, Oxford, United Kingdom, Copenhagen University Hospital, The Parker Institute, Bispebjerg and Frederiksberg, Denmark, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America, Royal National Hospital of Rheumatic Diseases, Bath, United Kingdom,